Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference82 articles.
1. Levine DS, Riff DS, Pruitt R, et al.: A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002, 97:1398–1407. This study verifies the dose effect of balsalazide as well as providing a direct comparison between balsalazide and mesalamine for the treatment of UC.
2. Green JR, Mansfield JC, Gibson JA, et al.: A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002, 16:61–68.
3. Mansfield JC, Giaffer MH, Cann PA, et al.: A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002, 16:69–77.
4. Kruis W, Schreiber S, Theuer D, et al.: Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001, 49:783–789.
5. Nugent SG, Kumar D, Rampton DS, Evans DF: Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001, 48:571–577.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献